vidutolimod + cemiplimab
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma
Trial Timeline
Nov 30, 2021 → Oct 31, 2024
NCT ID
NCT04916002About vidutolimod + cemiplimab
vidutolimod + cemiplimab is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Merkel Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04916002. Target conditions include Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma.
What happened to similar drugs?
0 of 1 similar drugs in Merkel Cell Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04916002 | Phase 2 | Terminated |
Competing Products
20 competing products in Merkel Cell Carcinoma